Plus Therapeutics Inc

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Plus Therapeutics advances trials, secures funding, and expands diagnostics

Plus Therapeutics demonstrates strong financial and operational progress with successful funding, grants, and trial advancements.
Strategic additions to the management team and diagnostic capabilities enhance the company's expertise and market positioning.
Challenges in financial management, regulatory processes, and dosing strategies require careful navigation for sustained growth and success.
Opportunities lie in FDA feedback, commercial launches, collaborations, and positive trial outcomes for future growth and market impact.

Plus Therapeutics Inc (PSTV) reports clinical progress amidst financial challenges

Plus Therapeutics Inc (PSTV) made significant clinical advancements in Q2 2024, while facing financial challenges. The company's strengths include positive trial results and supportive conference data, with opportunities for growth through expanded capabilities and funding access.

Plus Therapeutics progresses in leptomeningeal metastases program with strong financial backing

Plus Therapeutics is advancing promising treatments for leptomeningeal metastases with encouraging clinical data and FDA support.
Financially, the company is well-positioned with a solid cash balance, expected grant revenue, and access to diverse funding sources.
Strategic focus on upcoming events, milestones, and product launches underscores the company's commitment to innovation and growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Company Management and Principal Investigator of ReSPECT to Discuss Interim Data

Plus Therapeutics Announces Webinar to Present ReSPECT™ Glioblastoma Clinical Trial Update

Data and Safety Monitoring Board evaluated safety data in recommending cohort progression Data and Safety Monitoring Board evaluated safety data in recommending cohort progression

Plus Therapeutics Announces Initiation of Final Cohort of ReSPECT™ Glioblastoma Trial

Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q3 2020 Results - Earnings Call Transcript

– Receive d FDA O rphan D rug and Fast Track designations for novel glioblastoma radiotherapy –

Plus Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights

AUSTIN, Texas, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that it has been invited to participate in the Cancer Innovation Summit. The meeting, which is hosted by Health Tech Austin, is being held virtually on Thursday, October 22 from 12.00 to 3.00 p.m. EDT.

Plus Therapeutics to Present at the Cancer Innovation Summit

AUSTIN, Texas, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients’ lives, today announced that the company will report 2020 third quarter financial results on Thursday, October 22, 2020, after market close. Subsequently, Plus Therapeutics’ management team will host a conference call and webcast at 5:00 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Plus Therapeutics to Announce Third Quarter 2020 Financial Results and Host Conference Call on October 22, 2020

AUSTIN, Texas, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced the appointment of five leading experts in the fields of neurological surgery and neuro-oncology to its Clinical Advisory Board (CAB). The CAB will advise the Company as it advances its nanoscale radiotherapeutics to treat rare brain and neurological cancers.

Plus Therapeutics Announces Brain Cancer Clinical Advisory Team

Accepted Abstract will Showcase Clinical Data on Investigational Drug Rhenium NanoLiposomes (RNL™) Accepted Abstract will Showcase Clinical Data on Investigational Drug Rhenium NanoLiposomes (RNL™)

ReSPECT Glioblastoma Clinical Trial Data to be Presented at 2020 Society for Neuro-Oncology Annual Meeting

AUSTIN, Texas, Sept.  15, 2020  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track designation for its lead investigational drug, Rhenium NanoLiposomes ( RNL  ™  ), for the treatment of patients with recurrent glioblastoma. As previously reported, the Company also received orphan drug designation from the FDA for RNL for the treatment of patients with glioblastoma.    

Plus Therapeutics Receives Fast Track Designation From FDA for Its Novel Glioblastoma Treatment

AUSTIN, Texas, Sept.  09, 2020  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that it has been invited to present at the  22nd H. C. Wainwright Annual Global Investment Conference , which is being held virtually on September 14-16, 2020.

Plus Therapeutics, Inc. to Present at the 22nd H.

AUSTIN, Texas, Sept.  03, 2020  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that it has been invited to present at the  9  th   Annual Gateway Conference , which is being held virtually on September 9-10, 2020.

Plus Therapeutics, Inc. to Present at the 9th Annual Gateway Conference on September 10, 2020

Plus Therapeutics (NASDAQ: PSTV) shares are trading higher Tuesday after the company announced the Food and Drug Administration has granted orphan drug designation for Rhenium NanoLiposomes for the treatment of patients with recurrent glioblastoma.

Why Plus Therapeutics Stock Is Trading Higher Today

AUSTIN, Texas, Aug.  28, 2020  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc (Exchange: PSTV) , today announced that it will be presenting at the LD 500 investor conference on Friday, September 4 at 10.20 AM ET. Dr. Marc Hedrick, President and CEO of Plus Therapeutics, will be hosting the presentation and answering questions from investors.

Plus Therapeutics, Inc. to Present at The LD 500 Virtual Conference

Plus Therapeutics, Inc.(PSTV) CEO Marc Hedrick on Q2 2020 Results - Earnings Call Transcript

AUSTIN, Texas, Aug.  10, 2020  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced financial and business results for its Second Quarter Fiscal Year 2020 ended June 30, 2020.

Plus Therapeutics Reports Second Quarter 2020 Financial and Business Results

AUSTIN, Texas, Aug.  03, 2020  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”) today announced that it will report its Second Quarter Fiscal Year 2020 financial results after the close of market on August 10, 2020. The company plans to hold a conference call and live audio webcast at 5:00 PM Eastern Time to discuss its financial results and provide a general business update.

Plus Therapeutics To Report Second Quarter Fiscal Year 2020 Financial Results And Corporate Update on August 10, 2020

AUSTIN, Texas, July  28, 2020  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”) today announced the successful completion of the fifth cohort of the ReSPECT Clinical Trial and expansion to a second clinical trial site, the UT Southwestern Medical Center in Dallas.

Plus Therapeutics Completes Fifth Dose Escalation Cohort of the ReSPECT™ Glioblastoma Clinical Trial and Expands Trial Sites

AUSTIN, Texas, July  23, 2020  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”) today announced that it will be presenting at the YAFO ACCESS CHINA - 2020 Summer Online Partnering Day on Thursday, July 30 at 10:00 pm EST.  Dr. Marc Hedrick, President and CEO of Plus Therapeutics, will be hosting the presentation and answering questions from investors.

Plus Therapeutics to Present at the YAFO Access China Partnering Conference on July 30, 2020

AUSTIN, Texas, July  06, 2020  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) today announced that the compensation committee of the Company’s board of directors approved an inducement grant of stock options to purchase a total of 40,000 shares of common stock to Dr. Gregory Stein with a grant date of June 29, 2020 and an exercise price equal to $2.11, the fair market value on the grant date and a total of an additional 40,000 shares of common stock to Andrew Sims with a grant date of February 6, 2020 and an exercise price equal to $2.23, the fair market value on the grant date.

Plus Therapeutics Announces Inducement Stock Grants

Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q1 2020 Results - Earnings Call Transcript

AUSTIN, Texas, May  14, 2020  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced financial and business results for its first quarter fiscal year 2020 ended March 31, 2020.

Plus Therapeutics Reports First Quarter 2020 Financial and Business Results

AUSTIN, Texas, May  11, 2020  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”, “Plus”), today announced the closing of its previously announced definitive agreement to license multiple rare cancer product candidates from private Texas-based radiotherapeutic company NanoTx Therapeutics, Inc.

Plus Therapeutics Announces Closing of Agreement To License Novel Oncology Platform

AUSTIN, Texas, April  06, 2020  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that it is donating personal protective equipment to San Diego’s Scripps Health for distribution to its front-line doctors, nurses and other health-care practitioners caring for patients affected by the COVID-19 pandemic.

Plus Therapeutics Donates Personal Protective Equipment to Scripps Health to Confront COVID-19 Pandemic

AUSTIN, Texas, April  01, 2020  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that Dr. Gregory Stein has joined the Company as Senior Vice President of Clinical Development.

Plus Therapeutics Announces Dr. Gregory Stein as Head of Clinical Development

Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2019 Results Conference Call March 30, 2020 5:00 PM ET

News for Plus Therapeutics Inc Stock (PSTV)